Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
The New York Times - June 17, 2005
Janny Scott
The Office for Human Research Protections informed Columbia in a letter last month that the medical center's institutional review board had "failed to obtain sufficient information" concerning the selection of foster children as subjects, the process for getting their parents' or guardians' permission and certain additional safeguards.
The exact nature and significance of the violations were unclear yesterday. A spokeswoman for the agency, Pat El-Hinnawy, declined to say what information the review board had failed to obtain, whether the information would have affected the board's decision to approve the projects and whether any children were harmed.
The findings come at a time when questions have been raised nationally about the participation of foster children in drug trials during the 1980's and 1990's, when hundreds of babies in New York City alone were born H.I.V.-positive and when there were at first no treatments approved for children.
The city's Administration for Children's Services has hired the Vera Institute of Justice to investigate charges that the city inappropriately allowed foster children to take part.
The agency has said that it has found no evidence that it acted wrongly. Some 465 foster children took part between 1988 and 2001, the agency says.
Under federal regulations, foster children may participate in clinical trials as long as a parent or guardian has given permission, and if the risk is minimal or there is some prospect of direct benefit for the child. All clinical trials, even with adults, must have the approval of the institutional review board in the center where the trial is taking place.
The four trials cited in the letter were supported by the National Institutes of Health and involved dozens of medical centers nationwide. They occurred between 1993 and 2002. In a statement, a Columbia spokeswoman said the studies "were instrumental in extending lifesaving H.I.V. treatments to children."
"We stand behind the clinical aspects of these trials," Marilyn Castaldi, the spokeswoman, said in an interview. "It's not an issue of safety or harm."
050617
NYT050614
Copyright © 2005 - The New York Times Company. All Rights Reserved. All New York Times articles contained on the AEGiS web site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of The New York Times Company. You may not alter or remove any trademark, copyright or other notice from copies of the content. However, you may download articles (one machine readable copy and one print copy per page) for your personal, noncommercial use only.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .